HGS is a commercially focused biopharmaceutical company with a pipeline of novel drugs that includes three promising products in late-stage development – one already commercialized and two moving toward commercialization: BENLYSTA (belimumab) has successfully completed one of two pivotal Phase 3 trials in systemic lupus, ZALBIN (albinterferon alfa-2b) has successfully completed two Phase 3 trials in chronic hepatitis C, and Raxibacumab is currently pending priority review by FDA for inhalation anthrax.
CSRHub includes data on Training, Health & Safety, mutual funds investment, ESG, CSR, Sustainable Accounting Standards Board, and Environmental Protection Agency.
We Harmonize Global ESG Data
Your title or message
Sources{{sources_count}}
for
Companies{{companies_count}}
in
Countries{{countries_count}}
Your title or message
Summary of the data sources currently reporting on Human Genome Sciences, Inc. and some examples